A TROPiCS-02 trial analysis confirms the clinically meaningful OS benefit of sacituzumab govitecan over single-agent chemotherapy in patients with pretreated, endocrine-resistant HR+/HER2-negative metastatic breast cancer. #bcsm #MBCC24 cancernetwork.com/view/20-final-…

With a substantial proportion of patients completing 3 years of ribociclib treatment, NATALEE continues to show a significant iDFS improvement with ribociclib plus nonsteroidal aromatase inhibitors. #bcsm #MBCC24 cancernetwork.com/view/21-riboci…

Durable clinical activity with vepdegestrant at 200 mg daily was seen in heavily pretreated patients with ER+/HER2– advanced breast cancer. #bcsm #MBCC24 cancernetwork.com/view/22-update…

We are so proud to announce that our very own co-founder and CEO @JPBEATSABAR has been nominated for a Multicultural Business & Community Champion Awards 'Community Unsung Hero'. VOTING CLOSES ON 07/08/24 Vote here bit.ly/4fg1MI9 #MBCC24 #MBCCAwards #Beatsabar

Tinga has been shortlisted for the Community Unsung Hero Award at the Multicultural Business & Community Champion Awards! 🎊 Read more: bit.ly/4d629nk Join us in supporting Tinga by voting today: bit.ly/4fg1MI9 #CareUK #MBCC24 #MBCCAwards

We are excited to share that Tinga has been shortlisted for the Community Unsung Hero Award at the Multicultural Business and Community Champion (MBCC) awards. This nomination is a testament to Tinga's hard work. Vote for Tinga here: bit.ly/4fg1MI9 #MBCC24 #MBCCAwards

E. Shelley Hwang, MD, MPH, on Optimizing the Management of DCIS ascopost.com/issues/june-10… Shelley Hwang Duke University #bcsm #DCIS #breastcancer #oncology #MBCC24

Novel Approaches Show Early Activity in Endocrine-Resistant Breast Cancer ascopost.com/issues/may-25-… #MBCC24 #bcsm #breastcancer #oncology

At #MBCC24 last month, Dr. Rhiana Menen, MD demonstrated how Magtrace allows you to treat 20% more patients each month. Read the full poster to see the many other benefits of switching 👇

.Neil Iyengar discusses the 41st Annual Miami Breast Cancer Conference in the April Letter to Reader for ONCOLOGY. #bcsm #MBCC24 | PER cancernetwork.com/view/updates-i…

#ICYMI we were in Florida for the 41st #MiamiBreastCancerConference. It was a pleasure to meet fellow oncology experts and discuss our latest breast cancer research. #MBCC24

#PreludeDx was honored to have its #DCISionRT test discussed in a plenary session at #MBCC24. Shelley Hwang from Duke Cancer discussed the results presented in IJROBP - The Red Journal – The Red Journal. To read the journal article bit.ly/3IDBf8v #bcsm

At #MBCC24, Patricia Jakel, oncology nurse consultant and professor at UCLA School of Nursing, spoke about side effect management #BreastCancerSurvivors should know about. #BCSM Read more: curetoday.com/view/addressin…

Kelli Corona and Lauren Carpenter from the FLORIDA College of Pharmacy's Jacksonville campus made history earlier this month by becoming the first Pharm.D. students to have their research presented at the Miami Breast Cancer Conference. #mbcc24

Dr. W. Fraser Symmans of MD Anderson Cancer Center presented about circulating tumor DNA and circulating tumor cells in breast cancer at #MBCC24 and the CURE® Educated Patient® Breast Cancer Summit. #BCSM Read here: curetoday.com/view/ctdna-wil…

At #MBCC24, Dr. Kevin Kalinsky (Kevin Kalinsky, MD, MS, FASCO) of Winship Cancer Institute of Emory University explained the difference between genetic testing and genomic testing for certain patients with #BreastCancer, along with available treatments. #BCSM Read here: curetoday.com/view/differenc…

A #BreastCancerSurvivor and a patient advocate spoke with CURE® at #MBCC24 about the importance of both mental and physical health during #BreastCancer. #BCSM Read here: curetoday.com/view/rethinkin…

At #MBCC24, Dr. Laura Huppert (Laura Huppert, MD) of the University of California San Francisco (UC San Francisco) explained that germline genetic testing helps identify potential #BreastCancer mutations such as BRCA. #BCSM Read more about it: curetoday.com/view/why-all-p…

ICYMI: Hope Rugo of UCSF Helen Diller Family Comprehensive Cancer Ctr discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer. #MBCC24 #bcsm onclive.com/view/dr-rugo-o…